Profile data is unavailable for this security.
About the company
Hypera SA, formerly Hypermarcas SA, is a Brazil-based company engaged in the pharmaceuticals sector. The Company’s major business units include Branded Prescription, Consumer Health and Branded Generics. Branded Prescription is present in the main therapeutic classes in Brazil and it operates in the Primary Care segment under the umbrella brand Mantecorp Farmasa. The Branded Prescription unit also acts as Mantecorp Skincare in dermocosmetics, with products recommended by dermatologists. Consumer Health offers non-prescription drugs, with brands such as Apracur, Benegrip, Coristina d, Engov, Epocler and Estomazil, among others. The Consumer Health unit also operates in nutritionals and vitamin supplements, with brands such as Tamarine, Vitasay, Biotonico Fontoura and Zero-Cal. Branded Generics operates under the Neo Quimica brand.
- Revenue in BRL (TTM)8.04bn
- Net income in BRL1.70bn
- Incorporated2001
- Employees9.00k
- LocationHypera SARua Nova Cidade, 404, Vila OlimpiaSAO PAULO 04.547-070BrazilBRA
- Phone+55 1 136274206
- Fax+55 1 136274371
- Websitehttps://www.hypera.com.br/
| Holder | Shares | % Held |
|---|---|---|
| Capital Research & Management Co. (International Investors)as of 09 Apr 2024 | 65.87m | 10.40% |
| Capital Research & Management Co. (World Investors)as of 31 Mar 2024 | 60.26m | 9.51% |
| BV Distribuidora de T�tulos e Valores Mobili�rios Ltda.as of 09 Apr 2024 | 32.40m | 5.12% |
| The Vanguard Group, Inc.as of 05 Apr 2024 | 15.84m | 2.50% |
| Fidelity Management & Research Co. LLCas of 29 Feb 2024 | 13.72m | 2.17% |
| BlackRock Fund Advisorsas of 04 Apr 2024 | 12.47m | 1.97% |
| MFS International (UK) Ltd.as of 31 Mar 2024 | 7.96m | 1.26% |
| UBS Asset Management (Singapore) Ltd.as of 31 Dec 2023 | 7.58m | 1.20% |
| Vontobel Asset Management AGas of 28 Mar 2024 | 7.41m | 1.17% |
| Grandeur Peak Global Advisors LLCas of 31 Jan 2024 | 4.44m | 0.70% |
